Article Text

Download PDFPDF
Rilazole for amyotrophic lateral sclerosis
  • Relevant BNF section: 4.9.3


Around one in 20,000 adults in the UK will develop amyotrophic lateral sclerosis, the commonest variant of motor neurone disease. Riluzole (▼Rilutek - Rhône-Poulenc Rorer) was launched in the UK in August 1996 as "the first anti-excitotoxic agent proven to extend life in amyotrophic lateral sclerosis". We review the clinical data on the effectiveness of riluzole and assess its place in the management of amyotrophic lateral sclerosis, a condition that is invariably fatal and has a median survival time from symptom onset of about 2.5 years.1

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

  • Relevant BNF section: 4.9.3

View Full Text